- Home
- MRNA vs ILMN Comparison
MRNA vs ILMN Comparison
Compare MRNA & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- ILMN
- Stock Information
- Founded
- MRNA 2010
- ILMN 1998
- Country
- MRNA United States
- ILMN United States
- Employees
- MRNA N/A
- ILMN N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- ILMN Medical Specialities
- Sector
- MRNA Health Care
- ILMN Health Care
- Exchange
- MRNA Nasdaq
- ILMN Nasdaq
- Market Cap
- MRNA 13.4B
- ILMN 13.1B
- IPO Year
- MRNA 2018
- ILMN 2000
- Fundamental
- Price
- MRNA $34.15
- ILMN $109.30
- Analyst Decision
- MRNA Hold
- ILMN Buy
- Analyst Count
- MRNA 20
- ILMN 17
- Target Price
- MRNA $46.76
- ILMN $124.35
- AVG Volume (30 Days)
- MRNA 9.4M
- ILMN 2.3M
- Earning Date
- MRNA 08-01-2025
- ILMN 07-31-2025
- Dividend Yield
- MRNA N/A
- ILMN N/A
- EPS Growth
- MRNA N/A
- ILMN N/A
- EPS
- MRNA N/A
- ILMN N/A
- Revenue
- MRNA $3,177,000,000.00
- ILMN $4,337,000,000.00
- Revenue This Year
- MRNA N/A
- ILMN N/A
- Revenue Next Year
- MRNA $9.70
- ILMN $3.15
- P/E Ratio
- MRNA N/A
- ILMN N/A
- Revenue Growth
- MRNA N/A
- ILMN N/A
- 52 Week Low
- MRNA $23.15
- ILMN $68.70
- 52 Week High
- MRNA $125.68
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- MRNA 64.57
- ILMN 73.79
- Support Level
- MRNA $30.88
- ILMN $92.25
- Resistance Level
- MRNA $35.59
- ILMN $99.34
- Average True Range (ATR)
- MRNA 1.48
- ILMN 3.61
- MACD
- MRNA 0.11
- ILMN 0.66
- Stochastic Oscillator
- MRNA 74.05
- ILMN 95.79
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.